Resumo

PAVON MORAN, Valia; HERNANDEZ RAMIREZ, Porfirio; JAIME FAGUNDO, Juan Carlos  e  AGRAMONTE LLANES, Olga. Imatinib in chronic myeloid leukemia. Rev Cubana Hematol Inmunol Hemoter [online]. 2005, vol.21, n.3, pp. 0-0. ISSN 1561-2996.

Chronic myeloid leukemia (CML) was the first neoplasia in which it was possible to present a model of genotype that served as a target for a molecular action therapy. The activation of multiple ways of transduction signals in the cells with the BCR-ABL gene favors the increase of the cellular proliferation, interferes the apoptosis, and perturbs the interaction with the extracellular matrix and the stroma. The introduction of Imatinib in the treatment of CML has modified the evolution and prognosis of this disease. Imatinib has proved to have a high level of efficiency associated with a smaller number of adverse reactions on being compared with the regimens based on interferon and hydroxyurea

Palavras-chave : Chronic myeloid leukemia; Philadelphia chromosome; BCR-ABL; Imatinib.